The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.
Margaret K. Callahan
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb
Research Funding - AstraZeneca; Bristol-Myers Squibb
Patrick Alexander Ott
No relevant relationships to disclose
Kunle Odunsi
Research Funding - MedImmune
Stephane V. Bertolini
Employment or Leadership Position - Ludwig Institute for Cancer Research
Research Funding - MedImmune
Linda S. Pan
Employment or Leadership Position - Ludwig Institute for Cancer Research
Ralph Rudolph Venhaus
Research Funding - MedImmune
Joyson Joseph Karakunnel
Employment or Leadership Position - MedImmune
Stock Ownership - MedImmune
F. Stephen Hodi
Consultant or Advisory Role - MedImmune
Research Funding - MedImmune
Jedd D. Wolchok
Consultant or Advisory Role - MedImmune
Research Funding - MedImmune
Other Remuneration - MedImmune